Kymera Therapeutics Stock Buy Hold or Sell Recommendation
| KYMR Stock | USD 44.98 1.47 3.38% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Kymera Therapeutics is 'Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Kymera Therapeutics given historical horizon and risk tolerance towards Kymera Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Kymera Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Kymera Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide. Note, we conduct extensive research on individual companies such as Kymera and provide practical buy, sell, or hold advice based on investors' constraints. Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Kymera |
Execute Kymera Therapeutics Buy or Sell Advice
The Kymera recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Kymera Therapeutics. Macroaxis does not own or have any residual interests in Kymera Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Kymera Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Kymera Therapeutics Trading Alerts and Improvement Suggestions
| Kymera Therapeutics generated a negative expected return over the last 90 days | |
| Kymera Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 78.59 M. Net Loss for the year was (146.96 M) with loss before overhead, payroll, taxes, and interest of (117.42 M). | |
| Kymera Therapeutics currently holds about 392.31 M in cash with (102.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.61. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Kymera Therapeutics Now Covered by Stephens - MarketBeat |
Kymera Therapeutics Returns Distribution Density
The distribution of Kymera Therapeutics' historical returns is an attempt to chart the uncertainty of Kymera Therapeutics' future price movements. The chart of the probability distribution of Kymera Therapeutics daily returns describes the distribution of returns around its average expected value. We use Kymera Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Kymera Therapeutics returns is essential to provide solid investment advice for Kymera Therapeutics.
| Mean Return | -0.03 | Value At Risk | -5.51 | Potential Upside | 4.84 | Standard Deviation | 3.19 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Kymera Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Kymera Stock Institutional Investors
The Kymera Therapeutics' institutional investors refer to entities that pool money to purchase Kymera Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | Rock Springs Capital Management Lp | 2024-06-30 | 1.2 M | Geode Capital Management, Llc | 2024-06-30 | 1.1 M | Jennison Associates Llc | 2024-09-30 | 797.7 K | Deep Track Capital, Lp | 2024-09-30 | 600.3 K | Woodline Partners Lp | 2024-06-30 | 517.8 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 472.6 K | Goldman Sachs Group Inc | 2024-06-30 | 462.3 K | Eventide Asset Management, Llc | 2024-06-30 | 462.1 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 6.4 M | Baker Bros Advisors Lp | 2024-09-30 | 6 M |
Kymera Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 36.3M | (45.2M) | 21.5M | 20.4M | 41.3M | 43.3M | |
| Net Borrowings | (371K) | (554K) | (849K) | (1.1M) | (1.0M) | (1.1M) | |
| Free Cash Flow | 17.4M | 79.0M | (130.5M) | (155.9M) | (137.3M) | (130.4M) | |
| Depreciation | 825K | 1.8M | 2.4M | 3.0M | 3.6M | 2.2M | |
| Capital Expenditures | 532K | 9.1M | 1.6M | 2.8M | 34.5M | 36.2M | |
| Net Income | (41.2M) | (45.6M) | (100.2M) | (154.8M) | (147.0M) | (139.6M) | |
| End Period Cash Flow | 77.8M | 32.6M | 54.1M | 74.5M | 115.8M | 72.6M | |
| Change To Netincome | 1.6M | 7.1M | 25.0M | 35.5M | 40.8M | 42.8M |
Kymera Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Kymera Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Kymera Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Kymera stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.02 | |
β | Beta against Dow Jones | -0.22 | |
σ | Overall volatility | 3.06 | |
Ir | Information ratio | -0.04 |
Kymera Therapeutics Volatility Alert
Kymera Therapeutics exhibits very low volatility with skewness of 0.06 and kurtosis of 0.57. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Kymera Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Kymera Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Kymera Therapeutics Fundamentals Vs Peers
Comparing Kymera Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Kymera Therapeutics' direct or indirect competition across all of the common fundamentals between Kymera Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Kymera Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Kymera Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Kymera Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Kymera Therapeutics to competition |
| Fundamentals | Kymera Therapeutics | Peer Average |
| Return On Equity | -0.26 | -0.31 |
| Return On Asset | -0.15 | -0.14 |
| Profit Margin | (1.91) % | (1.27) % |
| Operating Margin | (19.28) % | (5.51) % |
| Current Valuation | 2.36 B | 16.62 B |
| Shares Outstanding | 64.77 M | 571.82 M |
| Shares Owned By Insiders | 1.27 % | 10.09 % |
| Shares Owned By Institutions | 98.73 % | 39.21 % |
| Number Of Shares Shorted | 9.16 M | 4.71 M |
| Price To Book | 3.16 X | 9.51 X |
| Price To Sales | 32.18 X | 11.42 X |
| Revenue | 78.59 M | 9.43 B |
| Gross Profit | (117.42 M) | 27.38 B |
| EBITDA | (143.2 M) | 3.9 B |
| Net Income | (146.96 M) | 570.98 M |
| Cash And Equivalents | 392.31 M | 2.7 B |
| Cash Per Share | 7.61 X | 5.01 X |
| Total Debt | 84.67 M | 5.32 B |
| Debt To Equity | 0.04 % | 48.70 % |
| Current Ratio | 4.60 X | 2.16 X |
| Book Value Per Share | 13.79 X | 1.93 K |
| Cash Flow From Operations | (102.83 M) | 971.22 M |
| Short Ratio | 24.12 X | 4.00 X |
| Earnings Per Share | (2.34) X | 3.12 X |
| Price To Earnings To Growth | 0.64 X | 4.89 X |
| Target Price | 57.76 | |
| Number Of Employees | 184 | 18.84 K |
| Beta | 2.22 | -0.15 |
| Market Capitalization | 2.82 B | 19.03 B |
| Total Asset | 575.76 M | 29.47 B |
| Retained Earnings | (530.75 M) | 9.33 B |
| Working Capital | 319.63 M | 1.48 B |
| Net Asset | 575.76 M |
Note: Acquisition by Albers Jeffrey W. of 16000 shares of Kymera Therapeutics at 31.2 subject to Rule 16b-3 [view details]
Kymera Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Kymera . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 32388.02 | |||
| Daily Balance Of Power | 0.5526 | |||
| Rate Of Daily Change | 1.03 | |||
| Day Median Price | 44.61 | |||
| Day Typical Price | 44.73 | |||
| Price Action Indicator | 1.1 | |||
| Period Momentum Indicator | 1.47 |
About Kymera Therapeutics Buy or Sell Advice
When is the right time to buy or sell Kymera Therapeutics? Buying financial instruments such as Kymera Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Kymera Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Emerging Markets Funds Thematic Idea Now
Emerging Markets Funds
Fund or Etfs that invest in markets of developing countries. The Emerging Markets Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.